يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Merle, Philippe"', وقت الاستعلام: 1.29s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

    المؤلفون: Merle, Philippe, Kudo, Masatoshi, Edeline, Julien, Bouattour, Mohamed, Cheng, Ann-Lii, Chan, Stephen, Yau, Thomas, Garrido, Marcelo, Knox, Jennifer, Daniele, Bruno, Breder, Valeriy, Lim, Ho Yeong, Ogasawara, Sadahisa, Cattan, Stéphane, Chao, Yee, B. Siegel, Abby, Martinez-Forero, Iván, Wei, Ziwen, Liu, C, Finn, Richard

    المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Kindai University, Oncogenesis, Stress, Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), National Taïwan University (NTU), The Chinese University of Hong Kong Hong Kong (CUHK), The University of Hong Kong (HKU), Pontificia Universidad Católica de Chile (UC), University of Toronto, N.N. Blokhin National Medical Research Center of Oncology, Sungkyunkwan University Suwon (SKKU), Chiba University, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Pharmaceutical Sciences, Merck & Co. Inc., Merck Research laboratories, Merck Sharp and Dohme (Merck & Co. Inc)-Merck Sharp and Dohme (Merck & Co. Inc), University of California Los Angeles (UCLA), University of California (UC)

    المصدر: ISSN: 2235-1795.

    مصطلحات موضوعية: Pembrolizumab, Medicine, Placebo, Sorafenib, Internal medicine, Clinical endpoint, Randomization, Gastroenterology, Hepatocellular carcinoma, Randomized controlled trial, Oncology, Cancer, Immunotherapy, Pathology, Alternative medicine, [SDV.CAN]Life Sciences [q-bio]/Cancer

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37901200; hal-04265920; https://hal.science/hal-04265920Test; https://hal.science/hal-04265920/documentTest; https://hal.science/hal-04265920/file/000529636.pdfTest; PUBMED: 37901200

    الإتاحة: https://doi.org/10.1159/000529636Test
    https://hal.science/hal-04265920Test
    https://hal.science/hal-04265920/documentTest
    https://hal.science/hal-04265920/file/000529636.pdfTest

    View record in BASE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240.

    المؤلفون: Ryoo, Baek‐Yeol1 (AUTHOR), Merle, Philippe2 (AUTHOR), Kulkarni, Amit S.3 (AUTHOR), Cheng, Ann‐Lii4 (AUTHOR), Bouattour, Mohamed5 (AUTHOR), Lim, Ho Yeong6 (AUTHOR), Breder, Valeriy7 (AUTHOR), Edeline, Julien8 (AUTHOR), Chao, Yee9 (AUTHOR), Ogasawara, Sadahisa10 (AUTHOR), Yau, Thomas11 (AUTHOR), Garrido, Marcelo12 (AUTHOR), Chan, Stephen L.13 (AUTHOR), Daniele, Bruno14 (AUTHOR), Norquist, Josephine M.3 (AUTHOR), Chen, Erluo3 (AUTHOR), Siegel, Abby B.3 (AUTHOR), Zhu, Andrew X.15,16 (AUTHOR), Finn, Richard S.17 (AUTHOR), Kudo, Masatoshi18 (AUTHOR) m-kudo@med.kindai.ac.jp

    المصدر: Cancer (0008543X). Mar2021, Vol. 127 Issue 6, p865-874. 10p.

    مصطلحات موضوعية: *DRUG efficacy, *PEMBROLIZUMAB, *QUALITY of life, *SORAFENIB

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث